TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$HIMS · Hims & Hers Stock Skyrockets 40%: What We Know Today | $HIMS
now playing · $HIMS
$HIMS···bullish· high· postravis hoium
Hims & Hers surges 40% on reported Novo Nordisk partnership for GLP-1 distribution
HIMS is positioned to become a major healthcare platform distributing branded GLP-1 drugs like Wegovy and Ozempic alongside compounded alternatives, leveraging its 2.5M user base…
$NVO···neutral· mediumtravis hoium
Novo Nordisk seeks new distribution channels as Ozempic/Wegovy revenue declines amid competition
NVO's GLP-1 revenue is flatlining and guided lower for 2026 due to Eli Lilly competition and price pressure, creating strong incentive to partner with telehealth platforms like HI…